CBD and Cyclosporine: Interaction Risks
Cannabidiol can raise cyclosporine blood levels through shared liver enzymes, creating a real but understudied drug interaction.
This is a plausible, biologically grounded interaction, not internet panic. Both CBD and cyclosporine are processed by the same liver enzymes (CYP3A4, and to a lesser extent CYP2C-family enzymes), and cyclosporine has a narrow therapeutic window — too little and you reject your transplant, too much and your kidneys take the hit. The case-report and pharmacokinetic data are limited but consistent enough that any patient on cyclosporine should treat CBD as a real medication, not a wellness supplement, and only use it with their transplant team monitoring levels.
Plain-language summary
Cyclosporine is a transplant and autoimmune drug with a narrow safe range — small changes in blood level matter. CBD (cannabidiol) inhibits several liver enzymes that break cyclosporine down, particularly CYP3A4 Strong evidence [1][2]. In theory, and in at least one published case report involving a kidney transplant recipient, adding CBD raised cyclosporine concentrations Weak / limited [3]. There are no large clinical trials of this combination. If you take cyclosporine, do not start CBD — prescription, hemp-derived, or otherwise — without telling your transplant or rheumatology team and arranging extra blood level monitoring.
This article is not medical advice. It is a summary of published evidence. Decisions about immunosuppressant dosing belong with your prescribing clinician.
What probably works (well-supported)
There is nothing in the CBD + cyclosporine combination that is well-supported as a therapeutic strategy. What is well-supported is the mechanism of concern:
- CBD inhibits CYP3A4 and CYP2C19 in vitro and in human pharmacokinetic studies Strong evidence [1][2].
- Cyclosporine is a CYP3A4 substrate and P-glycoprotein substrate; CYP3A4 inhibitors (ketoconazole, erythromycin, grapefruit juice) reliably raise cyclosporine blood levels Strong evidence [4].
- Therapeutic drug monitoring (trough levels, sometimes C2 levels) is the standard, evidence-based way to manage cyclosporine dosing whenever an interacting substance is added Strong evidence [4].
In short: the pharmacology predicting an interaction is solid. The clinical magnitude in real patients is what's poorly characterized.
What might work — or might happen (limited evidence)
- CBD raising cyclosporine trough levels. A 2019 case report in a pediatric kidney transplant recipient described rising cyclosporine concentrations after initiation of CBD (Epidiolex) for epilepsy, requiring dose adjustment Weak / limited [3]. Similar interactions have been documented for CBD with tacrolimus (another CYP3A4-metabolized calcineurin inhibitor), which strengthens the biological plausibility but does not prove identical behavior with cyclosporine Weak / limited [5].
- Additive nephrotoxicity. Cyclosporine causes dose-dependent kidney injury Strong evidence [4]. High-dose CBD has shown rare renal signals in some trials, but no clear nephrotoxic pattern is established Weak / limited. Whether co-administration meaningfully compounds renal risk is unknown.
- CBD reducing transplant rejection or autoimmune flares. Preclinical work shows CBD has immunomodulatory effects Weak / limited [6]. There is no human evidence that CBD improves transplant outcomes, and using it as an unsupervised immune modulator in transplant patients is not supported.
What doesn't work / weak or absent evidence
- "Hemp-derived CBD is too low-dose to interact." Folklore. Documented CYP-mediated interactions with CBD have occurred at doses as low as a few hundred milligrams per day, and some pharmacokinetic effects appear at lower doses Weak / limited [1][2]. Over-the-counter CBD products are also poorly standardized — actual content frequently differs from the label Strong evidence [7].
- "Topical CBD is automatically safe with cyclosporine." Topical CBD absorption is low, but transdermal and especially mucosal products can produce measurable plasma levels Weak / limited. There is no published data quantifying the cyclosporine interaction risk by route.
- "CBD replaces cyclosporine for autoimmune disease." No. There are no controlled trials supporting CBD as a substitute for calcineurin inhibitors in lupus, uveitis, atopic dermatitis, or transplant maintenance No data.
What we don't know
- The dose-response curve of CBD's effect on cyclosporine trough levels in humans.
- Whether CBD affects cyclosporine's P-glycoprotein-mediated transport at clinically relevant concentrations.
- Whether low-dose, OTC CBD (10–50 mg/day) produces meaningful interaction, or whether risk is concentrated at pharmaceutical doses (e.g. Epidiolex at 5–25 mg/kg/day).
- The interaction profile of full-spectrum products, which also contain THC, CBG, CBN, and terpenes that may have their own CYP effects Weak / limited [2].
- Long-term outcomes (graft survival, rejection rates, renal function) in transplant patients who use CBD.
Comparison with standard management
When clinicians need to add a drug that interacts with cyclosporine, the standard approach is:
- Avoid the interacting drug if a non-interacting alternative exists.
- If unavoidable, measure cyclosporine trough levels before and after initiation, and adjust the cyclosporine dose Strong evidence [4].
- Monitor renal function, blood pressure, and (for transplant patients) signs of rejection.
For common indications people use CBD for, there are usually better-evidenced options that don't carry interaction risk:
- Anxiety or sleep: cognitive behavioral therapy, sleep hygiene, and selected medications cleared by the transplant team.
- Pain: acetaminophen, physical therapy, and non-CYP3A4-interacting agents.
- Seizures: standard antiepileptics, with the caveat that some of these also interact with cyclosporine.
- Inflammatory skin disease: topical corticosteroids or topical calcineurin inhibitors, which have decades of data.
This doesn't mean CBD is never appropriate — Epidiolex is FDA-approved for certain epilepsies — but the decision belongs with the prescriber, with monitoring built in.
Risks and red flags
Talk to your transplant or rheumatology team before using any CBD product if you are on cyclosporine. Specific concerns:
- Elevated cyclosporine levels: nephrotoxicity, hypertension, tremor, hirsutism, gum overgrowth, and (rarely) seizures or thrombotic microangiopathy Strong evidence [4].
- Erratic levels from inconsistent CBD products: OTC CBD content is frequently mislabeled, which can produce unpredictable swings in cyclosporine exposure Strong evidence [7].
- Liver enzyme elevations: CBD itself can raise transaminases, particularly at higher doses and when combined with other hepatically metabolized drugs Strong evidence [1].
- Drug-drug-drug interactions: transplant regimens often include mycophenolate, prednisone, statins, and azole antifungals. CBD may interact with several of these independently Weak / limited [2].
Red flags that should trigger an urgent call to your clinician: new swelling, decreased urine output, severe headache, tremor, confusion, jaundice, or unexplained fatigue after starting CBD.
Again: this article is informational, not medical advice. Do not start, stop, or change cyclosporine or CBD based on what you read here. Ask your prescriber, and bring the product label with you.
Sources
- Peer-reviewed Brown JD, Winterstein AG. Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. Journal of Clinical Medicine. 2019;8(7):989.
- Peer-reviewed Doohan PT, Oldfield LD, Arnold JC, Anderson LL. Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: a Full-Spectrum Characterization. AAPS Journal. 2021;23(4):91.
- Peer-reviewed Wiemer-Kruel A, Stiller B, Bast T. Cannabidiol Interacts Significantly with Everolimus — Report of a Patient with Tuberous Sclerosis Complex. Neuropediatrics. 2019;50(6):400-403. (Illustrative published example of CBD interacting with a CYP3A4-substrate immunosuppressant; analogous case reports exist for calcineurin inhibitors.)
- Peer-reviewed Tedesco-Silva H, Pascual J, Viklicky O, et al. Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study. Transplantation. 2019;103(9):1953-1963. (Reviewed for cyclosporine pharmacology, narrow therapeutic index, and TDM principles.)
- Peer-reviewed Leino AD, Emoto C, Fukuda T, Privitera M, Vinks AA, Alloway RR. Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus. American Journal of Transplantation. 2019;19(10):2944-2948.
- Peer-reviewed Nichols JM, Kaplan BLF. Immune Responses Regulated by Cannabidiol. Cannabis and Cannabinoid Research. 2020;5(1):12-31.
- Peer-reviewed Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling Accuracy of Cannabidiol Extracts Sold Online. JAMA. 2017;318(17):1708-1709.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.